Inmunómica traslacional en neoplasias hematológicas
Publications (403) Publications in which a researcher has participated
2024
-
A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies
British Journal of Haematology
-
A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis
Cancers, Vol. 16, Núm. 9
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
-
Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry
Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 143-152
-
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Haematologica
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?
Hemato, Vol. 5, Núm. 2, pp. 171-179
-
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies
The Lancet HIV, Vol. 11, Núm. 2, pp. e106-e116
-
Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis
Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537
-
Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism
Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246
-
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Correction to: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review (Blood Cancer Journal, (2024), 14, 1, (24), 10.1038/s41408-023-00966-9)
Blood Cancer Journal
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256
-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313
-
Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis
Blood, Vol. 144, Núm. 8, pp. 873-887
-
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
Nature Communications, Vol. 15, Núm. 1
-
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Blood Cancer Journal, Vol. 14, Núm. 1
-
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227
-
Hypocortisolemic ASIA: a vaccine- and chronic infection-induced syndrome behind the origin of long COVID and myalgic encephalomyelitis
Frontiers in Immunology, Vol. 15